文献速递免疫规划传染病防控与疫情报告

单剂鼻内新城疫病毒(NDV)载体XBB.1.5变异株疫苗可减轻动物在同源变异株攻击下的疾病与传播

A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge.
PubMed 文献 · Vaccine · 2024-12-12

研究开发了表达XBB.1.5变异株刺突蛋白(融合前构象稳定)的鼻内新城疫病毒(NDV)载体疫苗(NDV-HXP-S)。在小鼠中,1或2剂鼻内免疫诱导全身和黏膜抗体应答,并保护其免受XBB.1.5变异株攻击;在仓鼠中,1或2剂鼻内免疫保护其免受同源变异株感染并减少病毒排放,在直接接触传播研究中为未免疫动物提供完全保护。

要点

  • 单剂或两剂鼻内NDV-HXP-S XBB.1.5疫苗在小鼠中诱导全身和黏膜抗体应答。
  • 单剂或两剂鼻内疫苗保护小鼠和仓鼠免受XBB.1.5变异株攻击。
  • 仓鼠直接接触传播研究中,免疫减少病毒排放并为未免疫动物提供完全保护。

核心结论

  • 鼻内接种变异株适配的NDV-HXP-S可诱导保护性黏膜免疫并降低传播率,单剂黏膜疫苗在小鼠和仓鼠中均显示出稳健的保护效力。

研究设计与样本

  • 研究开发表达XBB.1.5变异株刺突蛋白(融合前构象稳定)的鼻内NDV载体疫苗(NDV-HXP-S),在小鼠和仓鼠中进行免疫原性与攻毒保护及直接接触传播研究。

主要发现

  • 小鼠接受1或2剂鼻内live NDV-HXP-S XBB.1.5后诱导全身和黏膜抗体应答,并免受XBB.1.5变异株攻击。
  • 仓鼠接受1或2剂鼻内NDV-HXP-S XBB.1.5后免受同源变异株感染并减少病毒排放。
  • 仓鼠直接接触传播研究中,免疫组减少病毒排放,为未免疫动物提供完全保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rapid development of coronavirus disease 2019 (COVID-19) vaccines has helped mitigate the initial impact of the pandemic. However, in order to reduce transmission rates and protect more vulnerable and immunocompromised individuals unable to mount an effective immune response, development of a next-generation of mucosal vaccines is necessary. Here, we developed an intranasal Newcastle disease virus (NDV)-based vaccine expressing the spike of the XBB.1.5 variant stabilized in its pre-fusion conformation (NDV-HXP-S). We demonstrated that one or two intranasal immunizations with live NDV-HXP-S expressing the XBB.1.5 spike induces systemic and mucosal antibody responses in mice and protects them from a challenge with the XBB.1.5 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Furthermore, one or two intranasal vaccinations with NDV-HXP-S XBB.1.5 protected hamsters from variant matched infection and reduced virus emission, thereby providing complete protection to naïve animals in a direct contact transmission study. The data shown in this study supports the notion that intranasal vaccination with variant-adapted NDV-HXP-S induces protective mucosal immunity and reduces transmission rates, highlighting the robust protective efficacy of a single mucosal vaccination in mice and hamsters.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Slamanig S, Lemus N, Lai TY, et al. A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge. Vaccine. 2024. PMID: 39667115. doi:10.1016/j.vaccine.2024.126586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。